- Human pathology

Home > G. Tumoral pathology > NTRK3-rearranged fibrosarcoma

NTRK3-rearranged fibrosarcoma

Saturday 9 November 2019

NTRK3-rearranged fibrosarcomas

NTRK fusions in malignant tumors are therapeutic targets of tyrosine kinase inhibitors. Because they occur only in a small subset of mesenchymal tumors, knowledge regarding the corresponding histology is important to effectively identify patients who could benefit from targeted therapy.

CD34-positive fibrosarcoma of bone and soft tissue could be a good candidate for NTRK testing.

Paywall references

- Novel NTRK3 Fusions in Fibrosarcomas of Adults. Yamazaki F, Nakatani F, Asano N, Wakai S, Sekimizu M, Mitani S, Kubo T, Kawai A, Ichikawa H, Yoshida A. Am J Surg Pathol. 2019 Apr;43(4):523-530. doi : 10.1097/PAS.0000000000001194 PMID: 30520818